A Phase 1 study for ATA621 targeting both JC and BK viruses
Latest Information Update: 08 Aug 2018
Price :
$35 *
At a glance
- Drugs ATA 621 (Primary)
- Indications Human polyomavirus infections
- Focus Adverse reactions
- 08 Aug 2018 New trial record
- 01 Aug 2018 According to an Atara Biotherapeutics media release, this trial is planned to initiate in 2019.